Overview

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Status:
Not yet recruiting

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.

Phase:

Phase 2

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborators:

Institut Pasteur
Rockefeller University

Treatments:

Antibodies
Antibodies, Monoclonal